αvβ3-dependent cross-presentation of matrix metalloproteinase–2 by melanoma cells gives rise to a new tumor antigen

A large array of antigens that are recognized by tumor-specific T cells has been identified and shown to be generated through various processes. We describe a new mechanism underlying T cell recognition of melanoma cells, which involves the generation of a major histocompatibility complex class I–restricted epitope after tumor-mediated uptake and processing of an extracellular protein—a process referred to as cross-presentation—which is believed to be restricted to immune cells. We show that melanoma cells cross-present, in an αvβ3-dependent manner, an antigen derived from secreted matrix metalloproteinase–2 (MMP-2) to human leukocyte antigen A*0201-restricted T cells. Because MMP-2 activity is critical for melanoma progression, the MMP-2 peptide should be cross-presented by most progressing melanomas and represents a unique antigen for vaccine therapy of these tumors.

• Publication year

  2005

• Venue

  Journal of Experimental Medicine

• Publication date

  2005-07-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20042138PMID 15998788PMCID 2212908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cellular mechanisms governing cross-presentation of exogenous antigens

  2004cited by this paper
• A membrane protein required for dislocation of misfolded proteins from the ER

  2004cited by this paper
• A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol

  2004cited by this paper
• Molecular Role(s) for Integrins in Human Melanoma Invasion

  2004cited by this paper
• Long-term inhibition of glioma growth by systemic administration of human PEX.

  2003cited by this paper
• T-cell responses of vaccinated cancer patients.

  2003cited by this paper
• ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

  2003cited by this paper
• Identification of a Negatively Charged Peptide Motif within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte β2 Integrins*

  2003cited by this paper
• Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.

  2003cited by this paper
• Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.

  2002cited by this paper
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

  2002cited by this paper
• MHC class I antigen processing regulated by cytosolic proteolysis-short cuts that alter peptide generation.

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

  2002cited by this paper
• Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages.

  2002cited by this paper
• Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses

  2002cited by this paper
• Matrix Metalloproteinases of Normal Human Tissues

  2001cited by this paper
• Spatio-temporal images of growth-factor-induced activation of Ras and Rap1

  2001cited by this paper
• A novel role of metalloproteinase in cancer-mediated immunosuppression.

  2001cited by this paper
• Extracellular Matrix Metalloproteinase 2 Levels Are Regulated by the Low Density Lipoprotein-related Scavenger Receptor and Thrombospondin 2*

  2001cited by this paper
• Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression.

  2000cited by this paper
• A Processed Pseudogene Codes for a New Antigen Recognized by a Cd8+ T Cell Clone on Melanoma

  2000cited by this paper
• Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma

  2000cited by this paper
• Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2.

  2000cited by this paper
• Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15.

  2000cited by this paper
• Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression

  2000cited by this paper
• Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.

  1999cited by this paper
• Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization

  1999cited by this paper
• Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

  1999cited by this paper
• A giant protease with potential to substitute for some functions of the proteasome.

  1999cited by this paper
• Role of integrins in cancer: survey of expression patterns.

  1999cited by this paper
• Tumor-specific killer cells in paraneoplastic cerebellar degeneration

  1998cited by this paper
• Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.

  1998cited by this paper
• Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

  1998cited by this paper
• Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity.

  1998cited by this paper
• Melanoma‐associated antigens recognized by cytotoxic T lymphocytes

  1998cited by this paper
• Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation.

  1997cited by this paper
• Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.

  1997cited by this paper
• Activation of a recombinant membrane type 1‐matrix metalloproteinase (MT1‐MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)‐2

  1996cited by this paper
• Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3

  1996cited by this paper
• Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

  1996cited by this paper
• A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene

  1996cited by this paper
• Conformational constraints in protein degradation by the 20S proteasome

  1995cited by this paper
• Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus

  1994cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

  1994cited by this paper
• Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

  1994cited by this paper
• Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

  1994cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Recognition of shared melanoma antigen by HLA‐A2‐restricted cytolytic T cell clones derived from human tumor‐infiltrating lymphocytes

  1993cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• Metastatic potential correlates with enzymatic degradation of basement membrane collagen

  1980cited by this paper

• MMP2 is a immunotherapy related biomarker and correlated with cancer-associated fibroblasts infiltrate in melanoma

  2023cites this paper
• Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

  2022cites this paper
• MMP2 and TLRs modulate immune responses in the tumor microenvironment

  2021cites this paper
• Vitexin inhibited the invasion, metastasis, and progression of human melanoma cells by targeting STAT3 signaling pathway

  2020cites this paper
• MMP2 as an independent prognostic stratifier in oral cavity cancers

  2019cites this paper
• Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition

  2017cites this paper
• Pathophysiological roles of canstatin on myofibroblasts after myocardial infarction in rats

  2017cites this paper
• Exposure to Melan-A/MART-126-35 tumor epitope specific CD8+T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS)

  2016cites this paper
• Modulation of innate immunity in the tumor microenvironment

  2016cites this paper
• CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

  2015cites this paper
• Activation of Toll-like Rec eptor-2 by Endogenous Matrix Metalloproteinase-2 Modulates Dendritic-Cell-Mediated Inflammatory Responses Graphical

  2014cites this paper
• Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses.

  2014cites this paper
• Redirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics

  2013cites this paper
• Tumor-Produced Immune Regulating Factors

  2013cites this paper
• HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

  2013cites this paper
• HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

  2012cites this paper
• Matrix metalloproteinase-2 Promotes αvβ3 Integrin-Mediated Adhesion and Migration of Human Melanoma Cells by Cleaving Fibronectin

  2012cites this paper
• Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors

  2012cites this paper
• Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension.

  2012cites this paper
• Midkine as a Tumor-Shared Antigen

  2012cites this paper
• Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes

  2011cites this paper
• Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

  2011cites this paper
• Tumor‐reactive CD4+CD8αβ+ CD103+ αβT cells: A prevalent tumor‐reactive T‐cell subset in metastatic colorectal cancers

  2011cites this paper
• MUC1 immunotherapy.

  2010cites this paper
• Folding of Matrix Metalloproteinase-2 Prevents Endogenous Generation of MHC Class-I Restricted Epitope

  2010cites this paper
• The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen

  2010cites this paper
• The functioning antigens: beyond just as the immunological targets

  2009cites this paper
• ÉVALUATION DES PROTEINES MIDKINE ET SURVIVINE SUREXPRIMEES DANS LES CELLULES TUMORALES COMME CIBLES DE L'IMMUNITE CELLULAIRE ANTI-TUMORALE

  2009cites this paper
• A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients

  2009cites this paper
• Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells

  2009cites this paper
• MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

  2008cites this paper
• Bioactive Natural Peptides

  2008cites this paper
• Alpha‐v‐beta3 integrin expression in melanocytic nevi and cutaneous melanoma

  2007cites this paper
• Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.

  2007cites this paper
• Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients

  2007cites this paper
• Induction of antitumor immunity through xenoplacental immunization

  2006cites this paper
• Processing and presentation of tumor antigens and vaccination strategies.

  2006cites this paper
• Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.

  2006cites this paper
• Processing and presentation of tumor antigens and vaccination strategies.

  2006cites this paper
• Reverse immunology approach for the identification of CD8 T‐cell‐defined antigens: Advantages and hurdles

  2006cites this paper